| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dry Eye Syndromes | 118 | 2024 | 387 | 31.100 |
Why?
|
| Corneal Transplantation | 84 | 2024 | 321 | 22.490 |
Why?
|
| Cornea | 144 | 2024 | 1333 | 18.240 |
Why?
|
| Corneal Diseases | 43 | 2024 | 542 | 10.250 |
Why?
|
| Corneal Neovascularization | 46 | 2022 | 185 | 9.740 |
Why?
|
| Keratitis | 27 | 2024 | 241 | 7.380 |
Why?
|
| Graft Survival | 54 | 2024 | 3819 | 6.340 |
Why?
|
| Th17 Cells | 18 | 2024 | 794 | 5.710 |
Why?
|
| Graft Rejection | 50 | 2024 | 4445 | 5.640 |
Why?
|
| Graft vs Host Disease | 28 | 2024 | 3029 | 5.440 |
Why?
|
| Epithelium, Corneal | 24 | 2024 | 253 | 5.120 |
Why?
|
| Tears | 36 | 2024 | 251 | 4.730 |
Why?
|
| Lymphangiogenesis | 27 | 2021 | 172 | 4.570 |
Why?
|
| alpha-MSH | 7 | 2024 | 71 | 4.500 |
Why?
|
| Mice, Inbred BALB C | 89 | 2024 | 6216 | 4.270 |
Why?
|
| T-Lymphocytes, Regulatory | 24 | 2024 | 3080 | 4.250 |
Why?
|
| Endothelium, Corneal | 18 | 2024 | 215 | 4.130 |
Why?
|
| Conjunctiva | 31 | 2024 | 479 | 4.090 |
Why?
|
| Corneal Ulcer | 10 | 2023 | 128 | 3.920 |
Why?
|
| Disease Models, Animal | 67 | 2024 | 18252 | 3.570 |
Why?
|
| Keratoplasty, Penetrating | 24 | 2024 | 144 | 3.400 |
Why?
|
| Corneal Dystrophies, Hereditary | 7 | 2022 | 64 | 3.370 |
Why?
|
| Mice, Inbred C57BL | 110 | 2024 | 22169 | 3.310 |
Why?
|
| Antigen-Presenting Cells | 22 | 2024 | 964 | 3.300 |
Why?
|
| Trigeminal Nerve Diseases | 6 | 2022 | 49 | 3.170 |
Why?
|
| Microscopy, Confocal | 35 | 2023 | 1971 | 3.130 |
Why?
|
| Corneal Perforation | 5 | 2022 | 29 | 3.080 |
Why?
|
| Limbus Corneae | 11 | 2023 | 144 | 3.080 |
Why?
|
| Dendritic Cells | 29 | 2024 | 2747 | 2.950 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 17 | 2021 | 119 | 2.840 |
Why?
|
| Ophthalmic Nerve | 12 | 2017 | 42 | 2.730 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 4 | 2023 | 112 | 2.700 |
Why?
|
| Ophthalmic Solutions | 26 | 2024 | 313 | 2.680 |
Why?
|
| Conjunctivitis | 6 | 2021 | 155 | 2.550 |
Why?
|
| Eye Diseases | 10 | 2024 | 653 | 2.530 |
Why?
|
| Substance P | 6 | 2024 | 335 | 2.510 |
Why?
|
| Fluorescein | 12 | 2022 | 175 | 2.390 |
Why?
|
| Keratitis, Herpetic | 8 | 2022 | 77 | 2.330 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 7 | 2019 | 251 | 2.240 |
Why?
|
| Sickness Impact Profile | 6 | 2020 | 299 | 2.230 |
Why?
|
| Angiogenesis Inhibitors | 19 | 2022 | 2047 | 2.200 |
Why?
|
| Receptors, Neurokinin-1 | 7 | 2024 | 134 | 2.190 |
Why?
|
| Mice | 165 | 2024 | 81525 | 2.170 |
Why?
|
| Lymphatic Vessels | 15 | 2017 | 358 | 2.160 |
Why?
|
| Autoimmunity | 11 | 2021 | 1356 | 2.160 |
Why?
|
| Cataract | 9 | 2023 | 832 | 2.160 |
Why?
|
| Meibomian Glands | 21 | 2022 | 73 | 2.130 |
Why?
|
| Lacrimal Apparatus | 12 | 2022 | 223 | 2.070 |
Why?
|
| Animals | 222 | 2024 | 168459 | 2.040 |
Why?
|
| Corneal Edema | 4 | 2023 | 47 | 2.040 |
Why?
|
| Conjunctival Diseases | 7 | 2020 | 110 | 1.910 |
Why?
|
| Vascular Endothelial Growth Factor C | 13 | 2017 | 127 | 1.760 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 3 | 2023 | 113 | 1.760 |
Why?
|
| Autoimmune Diseases | 14 | 2022 | 2244 | 1.750 |
Why?
|
| Eye | 15 | 2021 | 712 | 1.750 |
Why?
|
| Visual Acuity | 30 | 2024 | 2672 | 1.730 |
Why?
|
| Tissue Adhesives | 5 | 2021 | 173 | 1.720 |
Why?
|
| Flow Cytometry | 29 | 2024 | 5869 | 1.700 |
Why?
|
| Fuchs' Endothelial Dystrophy | 3 | 2024 | 103 | 1.700 |
Why?
|
| Transplantation, Homologous | 41 | 2022 | 4806 | 1.630 |
Why?
|
| Immunologic Memory | 5 | 2024 | 1359 | 1.620 |
Why?
|
| Keratoconjunctivitis Sicca | 6 | 2021 | 26 | 1.610 |
Why?
|
| Thrombospondin 1 | 5 | 2019 | 257 | 1.580 |
Why?
|
| Fluorophotometry | 13 | 2021 | 40 | 1.540 |
Why?
|
| Th1 Cells | 13 | 2024 | 1036 | 1.540 |
Why?
|
| Immune Tolerance | 13 | 2024 | 2303 | 1.490 |
Why?
|
| Receptors, CCR7 | 5 | 2016 | 107 | 1.490 |
Why?
|
| Interferon-gamma | 16 | 2024 | 3162 | 1.470 |
Why?
|
| Artificial Organs | 4 | 2016 | 150 | 1.440 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 21 | 2017 | 427 | 1.430 |
Why?
|
| Endothelial Cells | 13 | 2023 | 3548 | 1.430 |
Why?
|
| Nerve Growth Factor | 2 | 2023 | 158 | 1.430 |
Why?
|
| Hypersensitivity, Delayed | 14 | 2013 | 490 | 1.390 |
Why?
|
| Hyperemia | 2 | 2021 | 221 | 1.370 |
Why?
|
| Interleukin-17 | 7 | 2022 | 912 | 1.340 |
Why?
|
| Corneal Stroma | 12 | 2015 | 171 | 1.340 |
Why?
|
| Administration, Topical | 21 | 2016 | 704 | 1.300 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 14 | 2016 | 299 | 1.290 |
Why?
|
| Interleukin-2 | 7 | 2020 | 1889 | 1.270 |
Why?
|
| Hydrogels | 4 | 2021 | 720 | 1.240 |
Why?
|
| Anti-Inflammatory Agents | 11 | 2021 | 1809 | 1.230 |
Why?
|
| Tissue Donors | 10 | 2020 | 2331 | 1.210 |
Why?
|
| Eye Infections, Fungal | 3 | 2017 | 100 | 1.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 21 | 2022 | 3492 | 1.180 |
Why?
|
| Cranial Nerve Diseases | 7 | 2017 | 113 | 1.180 |
Why?
|
| Adoptive Transfer | 6 | 2024 | 819 | 1.180 |
Why?
|
| Cell Movement | 19 | 2024 | 5203 | 1.130 |
Why?
|
| Neovascularization, Pathologic | 12 | 2021 | 2645 | 1.130 |
Why?
|
| Immunosuppressive Agents | 14 | 2018 | 4174 | 1.120 |
Why?
|
| Chemotaxis, Leukocyte | 6 | 2019 | 662 | 1.120 |
Why?
|
| Receptors, Chemokine | 8 | 2023 | 652 | 1.110 |
Why?
|
| Eye Proteins | 9 | 2021 | 633 | 1.100 |
Why?
|
| Male | 192 | 2024 | 360804 | 1.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2024 | 5671 | 1.080 |
Why?
|
| Sialoglycoproteins | 10 | 2005 | 315 | 1.080 |
Why?
|
| Acanthamoeba Keratitis | 3 | 2018 | 13 | 1.060 |
Why?
|
| Chemokine CCL21 | 3 | 2016 | 50 | 1.060 |
Why?
|
| Corneal Endothelial Cell Loss | 2 | 2017 | 25 | 1.050 |
Why?
|
| Adaptive Immunity | 5 | 2018 | 726 | 1.040 |
Why?
|
| Neovascularization, Physiologic | 10 | 2020 | 1349 | 1.030 |
Why?
|
| Serpins | 4 | 2021 | 247 | 1.030 |
Why?
|
| Corneal Opacity | 5 | 2019 | 47 | 1.030 |
Why?
|
| Anti-Allergic Agents | 2 | 2018 | 153 | 0.980 |
Why?
|
| Humans | 260 | 2024 | 761504 | 0.980 |
Why?
|
| Interleukin-10 | 5 | 2024 | 1175 | 0.960 |
Why?
|
| Fluorescent Dyes | 5 | 2017 | 1903 | 0.940 |
Why?
|
| Nerve Growth Factors | 4 | 2021 | 564 | 0.940 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 8 | 2017 | 546 | 0.930 |
Why?
|
| Inflammation | 19 | 2024 | 10773 | 0.930 |
Why?
|
| Forkhead Transcription Factors | 5 | 2024 | 1616 | 0.930 |
Why?
|
| Melanocortins | 1 | 2024 | 10 | 0.930 |
Why?
|
| Female | 166 | 2024 | 392644 | 0.930 |
Why?
|
| Immunity, Innate | 11 | 2023 | 3065 | 0.930 |
Why?
|
| Integrin alpha Chains | 1 | 2024 | 95 | 0.930 |
Why?
|
| Interleukin-7 | 2 | 2016 | 143 | 0.920 |
Why?
|
| Cytokines | 22 | 2023 | 7396 | 0.920 |
Why?
|
| Conjunctivitis, Allergic | 2 | 2022 | 125 | 0.920 |
Why?
|
| Mustard Gas | 1 | 2023 | 8 | 0.900 |
Why?
|
| Eye Pain | 3 | 2022 | 46 | 0.900 |
Why?
|
| Lymph Nodes | 16 | 2019 | 3466 | 0.870 |
Why?
|
| Monocytes | 10 | 2023 | 2570 | 0.870 |
Why?
|
| Lymphocyte Activation | 12 | 2019 | 5486 | 0.870 |
Why?
|
| Eye Injuries | 7 | 2023 | 227 | 0.850 |
Why?
|
| Eye Infections, Viral | 2 | 2021 | 60 | 0.850 |
Why?
|
| Antigens, CD | 10 | 2024 | 4003 | 0.840 |
Why?
|
| Langerhans Cells | 7 | 2007 | 170 | 0.830 |
Why?
|
| Ophthalmology | 5 | 2020 | 550 | 0.830 |
Why?
|
| Interleukin-1beta | 10 | 2018 | 999 | 0.820 |
Why?
|
| Wound Healing | 11 | 2023 | 2805 | 0.810 |
Why?
|
| Tumor Necrosis Factor-alpha | 18 | 2023 | 4352 | 0.790 |
Why?
|
| Gene Expression | 17 | 2022 | 7581 | 0.790 |
Why?
|
| Nerve Degeneration | 3 | 2016 | 748 | 0.780 |
Why?
|
| Prostheses and Implants | 4 | 2016 | 1271 | 0.770 |
Why?
|
| Aqueous Humor | 6 | 2019 | 153 | 0.770 |
Why?
|
| Scopolamine | 4 | 2016 | 93 | 0.760 |
Why?
|
| Oxidative Stress | 2 | 2024 | 3113 | 0.760 |
Why?
|
| Cyclosporine | 6 | 2018 | 778 | 0.760 |
Why?
|
| Immunity | 8 | 2016 | 996 | 0.760 |
Why?
|
| Interleukin-23 | 2 | 2020 | 201 | 0.750 |
Why?
|
| RNA, Messenger | 28 | 2016 | 12795 | 0.750 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2015 | 664 | 0.740 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2022 | 152 | 0.740 |
Why?
|
| Burns, Chemical | 6 | 2021 | 123 | 0.740 |
Why?
|
| Vision, Ocular | 3 | 2020 | 455 | 0.740 |
Why?
|
| Vision Disorders | 9 | 2023 | 1088 | 0.740 |
Why?
|
| Cyanoacrylates | 3 | 2020 | 46 | 0.740 |
Why?
|
| Middle Aged | 102 | 2024 | 220895 | 0.730 |
Why?
|
| Gene Expression Regulation | 11 | 2016 | 11903 | 0.730 |
Why?
|
| Receptors, Interleukin-1 | 8 | 2003 | 262 | 0.720 |
Why?
|
| Anterior Chamber | 5 | 2005 | 194 | 0.720 |
Why?
|
| Coculture Techniques | 9 | 2024 | 1341 | 0.720 |
Why?
|
| Leukocytes | 8 | 2019 | 2026 | 0.710 |
Why?
|
| Cell Count | 15 | 2019 | 1835 | 0.700 |
Why?
|
| Aged | 76 | 2024 | 169289 | 0.700 |
Why?
|
| Patients | 2 | 2017 | 907 | 0.700 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 16 | 2013 | 4575 | 0.690 |
Why?
|
| Janus Kinase 3 | 2 | 2017 | 76 | 0.680 |
Why?
|
| Transplantation Immunology | 4 | 2016 | 532 | 0.680 |
Why?
|
| Purinergic Antagonists | 1 | 2019 | 10 | 0.680 |
Why?
|
| Guaifenesin | 1 | 2019 | 5 | 0.670 |
Why?
|
| Glucocorticoids | 8 | 2018 | 2161 | 0.660 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 16 | 2018 | 3810 | 0.660 |
Why?
|
| Cells, Cultured | 23 | 2024 | 18965 | 0.660 |
Why?
|
| Major Histocompatibility Complex | 8 | 2007 | 870 | 0.660 |
Why?
|
| Interleukin-1 | 8 | 2007 | 1248 | 0.650 |
Why?
|
| Receptors, Purinergic | 1 | 2019 | 66 | 0.650 |
Why?
|
| Sjogren's Syndrome | 13 | 2018 | 237 | 0.650 |
Why?
|
| Glycoproteins | 12 | 2017 | 2203 | 0.640 |
Why?
|
| Denervation | 4 | 2013 | 265 | 0.630 |
Why?
|
| Recombinant Proteins | 7 | 2023 | 6534 | 0.620 |
Why?
|
| Interleukin-6 | 3 | 2024 | 3208 | 0.620 |
Why?
|
| Environment, Controlled | 3 | 2009 | 42 | 0.620 |
Why?
|
| T-Lymphocytes | 14 | 2021 | 10194 | 0.620 |
Why?
|
| Glaucoma | 3 | 2018 | 1185 | 0.610 |
Why?
|
| Isoantigens | 10 | 2016 | 551 | 0.600 |
Why?
|
| Killer Cells, Natural | 4 | 2022 | 2200 | 0.600 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2018 | 180 | 0.600 |
Why?
|
| Phacoemulsification | 2 | 2015 | 149 | 0.590 |
Why?
|
| CD40 Ligand | 4 | 2009 | 522 | 0.590 |
Why?
|
| Chemokines | 7 | 2012 | 960 | 0.590 |
Why?
|
| Aging | 10 | 2022 | 8708 | 0.580 |
Why?
|
| Stem Cells | 6 | 2023 | 3522 | 0.580 |
Why?
|
| Optics and Photonics | 1 | 2019 | 306 | 0.580 |
Why?
|
| Histocompatibility Antigens Class II | 8 | 2010 | 1435 | 0.580 |
Why?
|
| Membrane Transport Proteins | 11 | 2017 | 1035 | 0.580 |
Why?
|
| Organ Preservation | 2 | 2020 | 382 | 0.570 |
Why?
|
| Electrocoagulation | 3 | 2021 | 152 | 0.570 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2024 | 4369 | 0.570 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 107 | 0.570 |
Why?
|
| Chronic Disease | 13 | 2024 | 9318 | 0.570 |
Why?
|
| Disease Management | 5 | 2021 | 2508 | 0.560 |
Why?
|
| Methylprednisolone | 2 | 2016 | 385 | 0.560 |
Why?
|
| Adult | 78 | 2021 | 221177 | 0.560 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 1787 | 0.550 |
Why?
|
| Contact Lenses | 6 | 2024 | 138 | 0.550 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2023 | 1119 | 0.550 |
Why?
|
| Signal Transduction | 15 | 2021 | 23445 | 0.550 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2018 | 1880 | 0.550 |
Why?
|
| Phospholipase C gamma | 1 | 2016 | 131 | 0.540 |
Why?
|
| Mice, Inbred C3H | 6 | 2024 | 915 | 0.540 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2014 | 974 | 0.540 |
Why?
|
| Drug Delivery Systems | 4 | 2021 | 2226 | 0.540 |
Why?
|
| Retrospective Studies | 41 | 2024 | 80636 | 0.540 |
Why?
|
| Chemokine CCL19 | 1 | 2016 | 35 | 0.540 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2016 | 42 | 0.540 |
Why?
|
| Posterior Eye Segment | 1 | 2016 | 17 | 0.530 |
Why?
|
| Scleritis | 1 | 2016 | 96 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 8 | 2023 | 7407 | 0.520 |
Why?
|
| Docosahexaenoic Acids | 3 | 2019 | 908 | 0.520 |
Why?
|
| Interleukin-15 | 1 | 2016 | 185 | 0.520 |
Why?
|
| Membrane Glycoproteins | 5 | 2011 | 3702 | 0.520 |
Why?
|
| Immunity, Cellular | 3 | 2016 | 1560 | 0.510 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 1600 | 0.510 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 1626 | 0.510 |
Why?
|
| Anterior Eye Segment | 4 | 2016 | 143 | 0.510 |
Why?
|
| Eyelids | 1 | 2018 | 278 | 0.500 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 58976 | 0.500 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2012 | 592 | 0.500 |
Why?
|
| Thyroid Diseases | 1 | 2018 | 386 | 0.490 |
Why?
|
| Trigeminal Nerve | 2 | 2015 | 248 | 0.490 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2014 | 748 | 0.490 |
Why?
|
| Young Adult | 27 | 2021 | 59243 | 0.480 |
Why?
|
| Tobramycin | 1 | 2014 | 65 | 0.480 |
Why?
|
| Transplantation, Isogeneic | 6 | 2017 | 248 | 0.480 |
Why?
|
| Angiopoietin-1 | 1 | 2015 | 122 | 0.480 |
Why?
|
| Quality of Life | 10 | 2022 | 13367 | 0.480 |
Why?
|
| Body Size | 1 | 2017 | 463 | 0.470 |
Why?
|
| Green Fluorescent Proteins | 2 | 2019 | 2065 | 0.470 |
Why?
|
| DNA Damage | 1 | 2024 | 2446 | 0.470 |
Why?
|
| Follow-Up Studies | 24 | 2024 | 39106 | 0.470 |
Why?
|
| Rabbits | 13 | 2024 | 4772 | 0.470 |
Why?
|
| Immunity, Mucosal | 1 | 2017 | 483 | 0.460 |
Why?
|
| Ocular Hypertension | 1 | 2016 | 209 | 0.460 |
Why?
|
| Mucous Membrane | 1 | 2017 | 659 | 0.460 |
Why?
|
| Fibrillar Collagens | 1 | 2014 | 42 | 0.460 |
Why?
|
| Immunotherapy | 2 | 2020 | 4652 | 0.460 |
Why?
|
| Macrophages | 11 | 2023 | 5769 | 0.460 |
Why?
|
| Elastic Tissue | 1 | 2014 | 66 | 0.460 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2016 | 547 | 0.450 |
Why?
|
| E-Selectin | 1 | 2016 | 576 | 0.450 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 510 | 0.440 |
Why?
|
| Receptors, CCR5 | 2 | 2006 | 486 | 0.440 |
Why?
|
| Antibodies, Monoclonal | 8 | 2015 | 9177 | 0.430 |
Why?
|
| Peptides | 4 | 2011 | 4358 | 0.430 |
Why?
|
| Chemokine CCL20 | 1 | 2013 | 64 | 0.430 |
Why?
|
| Cell Proliferation | 10 | 2017 | 10445 | 0.430 |
Why?
|
| Health Surveys | 3 | 2020 | 4061 | 0.430 |
Why?
|
| Receptors, CCR6 | 1 | 2013 | 74 | 0.430 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2015 | 191 | 0.420 |
Why?
|
| Androstadienes | 1 | 2014 | 348 | 0.420 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 1989 | 0.420 |
Why?
|
| Epithelial Cells | 10 | 2023 | 3673 | 0.420 |
Why?
|
| Blood Vessels | 4 | 2017 | 1113 | 0.410 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 11076 | 0.410 |
Why?
|
| Muscarinic Antagonists | 1 | 2013 | 135 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2017 | 558 | 0.410 |
Why?
|
| Tacrolimus | 1 | 2016 | 733 | 0.410 |
Why?
|
| Apoptosis | 9 | 2020 | 9486 | 0.410 |
Why?
|
| Antibodies, Neutralizing | 5 | 2024 | 1943 | 0.400 |
Why?
|
| Optic Nerve Diseases | 1 | 2016 | 342 | 0.400 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2012 | 34 | 0.400 |
Why?
|
| Vascular Endothelial Growth Factor D | 5 | 2015 | 64 | 0.400 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2019 | 354 | 0.400 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 445 | 0.400 |
Why?
|
| Cross-Sectional Studies | 24 | 2023 | 26125 | 0.400 |
Why?
|
| Prospective Studies | 28 | 2022 | 54425 | 0.390 |
Why?
|
| RNA | 5 | 2024 | 2726 | 0.390 |
Why?
|
| bcl-X Protein | 2 | 2011 | 410 | 0.390 |
Why?
|
| Retinal Diseases | 5 | 2019 | 705 | 0.390 |
Why?
|
| Eye Infections | 3 | 2015 | 62 | 0.390 |
Why?
|
| Immunization | 3 | 2001 | 1228 | 0.390 |
Why?
|
| Catechin | 1 | 2011 | 69 | 0.390 |
Why?
|
| Nanoparticles | 2 | 2021 | 1959 | 0.380 |
Why?
|
| Bioprosthesis | 1 | 2016 | 591 | 0.380 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 1726 | 0.380 |
Why?
|
| Polychondritis, Relapsing | 1 | 2011 | 29 | 0.380 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 2014 | 509 | 0.380 |
Why?
|
| Eyelid Diseases | 6 | 2020 | 157 | 0.380 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2024 | 270 | 0.380 |
Why?
|
| Uveitis | 4 | 2019 | 395 | 0.370 |
Why?
|
| Pain Measurement | 3 | 2017 | 3550 | 0.370 |
Why?
|
| Intraocular Pressure | 7 | 2016 | 1294 | 0.370 |
Why?
|
| Bone Marrow Cells | 8 | 2014 | 2416 | 0.370 |
Why?
|
| Pyrimidines | 2 | 2014 | 3028 | 0.370 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2006 | 585 | 0.370 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2016 | 1802 | 0.370 |
Why?
|
| Double-Blind Method | 11 | 2019 | 12341 | 0.370 |
Why?
|
| Mesenchymal Stem Cells | 6 | 2021 | 1642 | 0.370 |
Why?
|
| Receptors, CCR2 | 2 | 2009 | 215 | 0.360 |
Why?
|
| Choroidal Neovascularization | 1 | 2014 | 363 | 0.360 |
Why?
|
| Descemet Membrane | 2 | 2022 | 71 | 0.360 |
Why?
|
| Lymphatic System | 5 | 2009 | 254 | 0.360 |
Why?
|
| Bone Marrow Transplantation | 2 | 2013 | 2693 | 0.350 |
Why?
|
| Immune System | 7 | 2011 | 796 | 0.350 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2015 | 3734 | 0.350 |
Why?
|
| Leadership | 1 | 2020 | 1385 | 0.350 |
Why?
|
| Xerophthalmia | 1 | 2009 | 12 | 0.350 |
Why?
|
| Severity of Illness Index | 10 | 2018 | 15842 | 0.350 |
Why?
|
| Cell Adhesion Molecules | 2 | 2011 | 1600 | 0.350 |
Why?
|
| Mice, Knockout | 15 | 2021 | 14414 | 0.340 |
Why?
|
| Retina | 5 | 2018 | 2659 | 0.340 |
Why?
|
| Lymphocyte Count | 3 | 2019 | 778 | 0.340 |
Why?
|
| Models, Animal | 7 | 2020 | 2112 | 0.340 |
Why?
|
| Chemokine CCL5 | 4 | 2007 | 214 | 0.340 |
Why?
|
| Azithromycin | 1 | 2011 | 199 | 0.340 |
Why?
|
| Androgens | 7 | 2003 | 1286 | 0.330 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2012 | 563 | 0.330 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2024 | 306 | 0.330 |
Why?
|
| Internet | 2 | 2021 | 3092 | 0.330 |
Why?
|
| Prevalence | 11 | 2022 | 15732 | 0.330 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1670 | 0.320 |
Why?
|
| Risk Factors | 31 | 2024 | 74206 | 0.320 |
Why?
|
| Homeostasis | 4 | 2017 | 3323 | 0.320 |
Why?
|
| Electrolysis | 3 | 2013 | 9 | 0.320 |
Why?
|
| Cataract Extraction | 2 | 2004 | 467 | 0.320 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 579 | 0.320 |
Why?
|
| Integrin alpha4beta1 | 1 | 2008 | 119 | 0.310 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 1463 | 0.310 |
Why?
|
| Cell Differentiation | 10 | 2020 | 11528 | 0.310 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2016 | 278 | 0.310 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 710 | 0.300 |
Why?
|
| Eye Burns | 3 | 2017 | 65 | 0.300 |
Why?
|
| Treatment Outcome | 19 | 2024 | 64680 | 0.300 |
Why?
|
| Tropicamide | 1 | 2007 | 22 | 0.290 |
Why?
|
| Integrin alpha1beta1 | 1 | 2007 | 8 | 0.290 |
Why?
|
| Growth Inhibitors | 1 | 2009 | 378 | 0.290 |
Why?
|
| Contrast Sensitivity | 2 | 2019 | 253 | 0.290 |
Why?
|
| Pyrroles | 1 | 2014 | 1125 | 0.290 |
Why?
|
| alpha-Linolenic Acid | 1 | 2008 | 144 | 0.290 |
Why?
|
| Macrophage Inflammatory Proteins | 3 | 2005 | 121 | 0.290 |
Why?
|
| Mydriatics | 1 | 2007 | 67 | 0.280 |
Why?
|
| Desiccation | 2 | 2024 | 78 | 0.280 |
Why?
|
| Linoleic Acid | 1 | 2008 | 158 | 0.280 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2019 | 561 | 0.280 |
Why?
|
| Transplantation Tolerance | 1 | 2012 | 605 | 0.280 |
Why?
|
| Lymphocyte Depletion | 1 | 2009 | 602 | 0.280 |
Why?
|
| Epithelium | 4 | 2018 | 1603 | 0.270 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 3712 | 0.270 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2007 | 139 | 0.270 |
Why?
|
| Uveitis, Anterior | 2 | 2017 | 102 | 0.270 |
Why?
|
| Pupil | 1 | 2007 | 146 | 0.270 |
Why?
|
| Incidence | 11 | 2024 | 21353 | 0.270 |
Why?
|
| Eye Neoplasms | 2 | 2005 | 307 | 0.270 |
Why?
|
| Streptozocin | 2 | 2024 | 194 | 0.270 |
Why?
|
| Cell Line | 5 | 2024 | 15601 | 0.270 |
Why?
|
| Immunophenotyping | 5 | 2018 | 1870 | 0.270 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 594 | 0.270 |
Why?
|
| Lipoxins | 1 | 2009 | 419 | 0.270 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 1136 | 0.260 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2005 | 51 | 0.260 |
Why?
|
| Microglia | 3 | 2019 | 1361 | 0.250 |
Why?
|
| Phosphoproteins | 2 | 2012 | 2448 | 0.250 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1403 | 0.250 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 529 | 0.250 |
Why?
|
| Piperidines | 1 | 2014 | 1656 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 5671 | 0.240 |
Why?
|
| Matrix Metalloproteinase 10 | 1 | 2024 | 11 | 0.240 |
Why?
|
| Adhesives | 2 | 2021 | 66 | 0.240 |
Why?
|
| Tomography, Optical Coherence | 4 | 2019 | 2917 | 0.240 |
Why?
|
| Time Factors | 11 | 2021 | 39967 | 0.230 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2011 | 1126 | 0.230 |
Why?
|
| Cell Survival | 4 | 2020 | 5791 | 0.230 |
Why?
|
| Fibrosis | 2 | 2024 | 2049 | 0.230 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2024 | 145 | 0.230 |
Why?
|
| Receptors, Melanocortin | 1 | 2024 | 23 | 0.230 |
Why?
|
| Mouth Mucosa | 2 | 2020 | 432 | 0.230 |
Why?
|
| Fibroblasts | 3 | 2014 | 4141 | 0.230 |
Why?
|
| Microscopy, Fluorescence | 6 | 2012 | 2645 | 0.230 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 4758 | 0.230 |
Why?
|
| Endothelium, Vascular | 2 | 2011 | 4431 | 0.230 |
Why?
|
| Phenotype | 7 | 2024 | 16591 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2013 | 1589 | 0.230 |
Why?
|
| Mechlorethamine | 1 | 2023 | 129 | 0.220 |
Why?
|
| Antigenic Variation | 1 | 2004 | 118 | 0.220 |
Why?
|
| Herpes Zoster Ophthalmicus | 2 | 2015 | 37 | 0.220 |
Why?
|
| Viral Proteins | 1 | 2011 | 1804 | 0.220 |
Why?
|
| Antioxidants | 1 | 2011 | 1668 | 0.220 |
Why?
|
| Disease Progression | 7 | 2024 | 13506 | 0.220 |
Why?
|
| Eye Infections, Bacterial | 3 | 2015 | 242 | 0.220 |
Why?
|
| Staining and Labeling | 3 | 2018 | 1085 | 0.220 |
Why?
|
| Blindness | 4 | 2018 | 584 | 0.220 |
Why?
|
| Oligopeptides | 1 | 2008 | 1187 | 0.210 |
Why?
|
| Immunomodulation | 2 | 2018 | 549 | 0.210 |
Why?
|
| Tissue Preservation | 1 | 2023 | 174 | 0.210 |
Why?
|
| Cytoprotection | 1 | 2023 | 200 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2013 | 1978 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 10766 | 0.210 |
Why?
|
| Neuroglia | 2 | 2018 | 956 | 0.210 |
Why?
|
| Swine | 3 | 2021 | 5915 | 0.210 |
Why?
|
| Disability Evaluation | 3 | 2017 | 1835 | 0.210 |
Why?
|
| Biological Availability | 2 | 2021 | 390 | 0.210 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 13380 | 0.210 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 2416 | 0.200 |
Why?
|
| Case-Control Studies | 10 | 2023 | 22176 | 0.200 |
Why?
|
| In Situ Nick-End Labeling | 4 | 2014 | 613 | 0.200 |
Why?
|
| Ovalbumin | 6 | 2015 | 677 | 0.200 |
Why?
|
| Trans-Activators | 1 | 2012 | 2856 | 0.200 |
Why?
|
| Acrylamides | 1 | 2024 | 260 | 0.200 |
Why?
|
| Adolescent | 20 | 2024 | 88319 | 0.200 |
Why?
|
| Photochemotherapy | 2 | 2017 | 823 | 0.200 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 2001 | 72 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 5 | 2012 | 1705 | 0.200 |
Why?
|
| Blotting, Western | 6 | 2017 | 5035 | 0.200 |
Why?
|
| Pilot Projects | 4 | 2019 | 8631 | 0.200 |
Why?
|
| Postoperative Complications | 8 | 2024 | 15631 | 0.200 |
Why?
|
| Ultraviolet Rays | 3 | 2024 | 1080 | 0.190 |
Why?
|
| Ligands | 3 | 2016 | 3272 | 0.190 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2021 | 74 | 0.190 |
Why?
|
| Consensus | 6 | 2022 | 3123 | 0.190 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2019 | 114 | 0.190 |
Why?
|
| Up-Regulation | 5 | 2024 | 4124 | 0.190 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 837 | 0.190 |
Why?
|
| Antirheumatic Agents | 3 | 2016 | 1372 | 0.190 |
Why?
|
| Eye Banks | 2 | 2020 | 40 | 0.190 |
Why?
|
| Blinking | 2 | 2012 | 133 | 0.190 |
Why?
|
| Sex Distribution | 4 | 2019 | 2281 | 0.190 |
Why?
|
| Silicone Elastomers | 1 | 2001 | 78 | 0.190 |
Why?
|
| Neutrophil Infiltration | 1 | 2023 | 390 | 0.180 |
Why?
|
| Eye Injuries, Penetrating | 3 | 2004 | 124 | 0.180 |
Why?
|
| Conjunctivitis, Viral | 1 | 2020 | 6 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2024 | 730 | 0.180 |
Why?
|
| Massachusetts | 3 | 2021 | 8830 | 0.180 |
Why?
|
| Drug Implants | 3 | 2012 | 230 | 0.180 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5336 | 0.180 |
Why?
|
| Guinea Pigs | 1 | 2022 | 1310 | 0.180 |
Why?
|
| Histamine | 1 | 2022 | 499 | 0.180 |
Why?
|
| Tensile Strength | 1 | 2021 | 330 | 0.180 |
Why?
|
| Cicatrix | 1 | 2007 | 798 | 0.180 |
Why?
|
| Eye Abnormalities | 2 | 2016 | 242 | 0.180 |
Why?
|
| Telemedicine | 1 | 2018 | 3051 | 0.180 |
Why?
|
| Cell Line, Transformed | 1 | 2021 | 867 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 978 | 0.170 |
Why?
|
| Adenoviridae | 1 | 2004 | 1084 | 0.170 |
Why?
|
| Interleukin-8 | 1 | 2023 | 695 | 0.170 |
Why?
|
| Interleukin-1alpha | 2 | 2011 | 86 | 0.170 |
Why?
|
| Gene Deletion | 2 | 2007 | 2665 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2017 | 256 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2019 | 4021 | 0.170 |
Why?
|
| Sutures | 2 | 2007 | 284 | 0.170 |
Why?
|
| Expectorants | 1 | 2019 | 22 | 0.170 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 137 | 0.160 |
Why?
|
| Blood Group Incompatibility | 1 | 2000 | 135 | 0.160 |
Why?
|
| Observer Variation | 2 | 2017 | 2606 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 12148 | 0.160 |
Why?
|
| Hypertension | 2 | 2018 | 8540 | 0.160 |
Why?
|
| Species Specificity | 2 | 2017 | 2414 | 0.160 |
Why?
|
| Androgen-Insensitivity Syndrome | 3 | 2003 | 33 | 0.160 |
Why?
|
| Interleukin-12 | 2 | 2017 | 584 | 0.160 |
Why?
|
| Antibodies | 2 | 2007 | 2418 | 0.160 |
Why?
|
| Antibodies, Blocking | 2 | 2009 | 243 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2005 | 1499 | 0.160 |
Why?
|
| Ciprofloxacin | 1 | 2020 | 312 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2014 | 2273 | 0.160 |
Why?
|
| Th2 Cells | 4 | 2013 | 1060 | 0.160 |
Why?
|
| Cell Death | 1 | 2024 | 1678 | 0.150 |
Why?
|
| Organ Culture Techniques | 1 | 2020 | 794 | 0.150 |
Why?
|
| Emulsions | 1 | 2018 | 152 | 0.150 |
Why?
|
| Feasibility Studies | 4 | 2023 | 5247 | 0.150 |
Why?
|
| Age Distribution | 3 | 2019 | 2880 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1189 | 0.150 |
Why?
|
| Linseed Oil | 1 | 2017 | 5 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2013 | 3429 | 0.150 |
Why?
|
| Physicians | 2 | 2013 | 4591 | 0.150 |
Why?
|
| China | 1 | 2024 | 2369 | 0.150 |
Why?
|
| Transplantation, Heterotopic | 1 | 2018 | 174 | 0.150 |
Why?
|
| Virulence | 1 | 2021 | 1303 | 0.150 |
Why?
|
| Exophiala | 1 | 2017 | 2 | 0.150 |
Why?
|
| Goblet Cells | 3 | 2007 | 298 | 0.150 |
Why?
|
| Eosinophils | 1 | 2022 | 950 | 0.140 |
Why?
|
| Optic Nerve Injuries | 1 | 2018 | 150 | 0.140 |
Why?
|
| Steroids | 3 | 2016 | 929 | 0.140 |
Why?
|
| Prosthesis Design | 2 | 2014 | 2115 | 0.140 |
Why?
|
| Diathermy | 1 | 2017 | 17 | 0.140 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2016 | 13 | 0.140 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 40 | 0.140 |
Why?
|
| Lectins, C-Type | 2 | 2011 | 585 | 0.140 |
Why?
|
| Cyclosporins | 1 | 2016 | 216 | 0.140 |
Why?
|
| United States | 15 | 2024 | 72334 | 0.140 |
Why?
|
| Laser Therapy | 1 | 2004 | 1092 | 0.140 |
Why?
|
| Axons | 2 | 2016 | 1674 | 0.140 |
Why?
|
| Receptors, CCR1 | 2 | 2007 | 30 | 0.130 |
Why?
|
| Transfection | 1 | 2004 | 5774 | 0.130 |
Why?
|
| Leukocyte Elastase | 1 | 2017 | 114 | 0.130 |
Why?
|
| Serum | 1 | 2017 | 209 | 0.130 |
Why?
|
| STAT5 Transcription Factor | 1 | 2016 | 265 | 0.130 |
Why?
|
| Lipid Metabolism | 6 | 2006 | 1902 | 0.130 |
Why?
|
| Morbidity | 1 | 2021 | 1750 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 1551 | 0.130 |
Why?
|
| Oxidation-Reduction | 2 | 2019 | 2231 | 0.130 |
Why?
|
| Dacryocystitis | 1 | 2016 | 68 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 6310 | 0.130 |
Why?
|
| Nasolacrimal Duct | 1 | 2016 | 79 | 0.130 |
Why?
|
| Doxycycline | 1 | 2017 | 344 | 0.120 |
Why?
|
| Mice, Inbred Strains | 4 | 2002 | 1762 | 0.120 |
Why?
|
| Tonometry, Ocular | 1 | 2016 | 235 | 0.120 |
Why?
|
| Polymers | 2 | 2021 | 1617 | 0.120 |
Why?
|
| Keratotomy, Radial | 1 | 1994 | 3 | 0.120 |
Why?
|
| Mucins | 3 | 2021 | 568 | 0.120 |
Why?
|
| Keratoconjunctivitis | 1 | 2015 | 40 | 0.120 |
Why?
|
| Humidity | 2 | 2007 | 205 | 0.120 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 513 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 4853 | 0.120 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2001 | 1208 | 0.120 |
Why?
|
| Keratoconus | 2 | 2017 | 112 | 0.120 |
Why?
|
| Pseudophakia | 1 | 2015 | 60 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 2 | 2016 | 1961 | 0.120 |
Why?
|
| Injections, Intraperitoneal | 2 | 2014 | 413 | 0.120 |
Why?
|
| Indazoles | 2 | 2015 | 304 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 632 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2004 | 3395 | 0.120 |
Why?
|
| Miniaturization | 1 | 2014 | 153 | 0.120 |
Why?
|
| Retinal Degeneration | 1 | 2018 | 413 | 0.120 |
Why?
|
| Osmolar Concentration | 2 | 2013 | 659 | 0.120 |
Why?
|
| Leprosy | 1 | 1994 | 126 | 0.110 |
Why?
|
| Lubricants | 1 | 2013 | 26 | 0.110 |
Why?
|
| Biocompatible Materials | 2 | 2019 | 1685 | 0.110 |
Why?
|
| Fish Oils | 1 | 2017 | 483 | 0.110 |
Why?
|
| Chemokine CXCL10 | 2 | 2008 | 316 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 14666 | 0.110 |
Why?
|
| Reference Values | 3 | 2016 | 4920 | 0.110 |
Why?
|
| P-Selectin | 1 | 2016 | 597 | 0.110 |
Why?
|
| Vitreous Hemorrhage | 1 | 1993 | 48 | 0.110 |
Why?
|
| Immunoprecipitation | 2 | 2017 | 878 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 891 | 0.110 |
Why?
|
| Chemokine CCL4 | 2 | 2005 | 126 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 629 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 20098 | 0.110 |
Why?
|
| Registries | 3 | 2024 | 8224 | 0.110 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2016 | 246 | 0.110 |
Why?
|
| NF-kappa B | 2 | 2015 | 2490 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 733 | 0.110 |
Why?
|
| Galectin 3 | 1 | 2015 | 240 | 0.110 |
Why?
|
| Choroid | 1 | 2015 | 360 | 0.110 |
Why?
|
| Sugar Phosphates | 1 | 2012 | 44 | 0.100 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 909 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2019 | 2645 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2009 | 2919 | 0.100 |
Why?
|
| Ophthalmic Artery | 1 | 2013 | 58 | 0.100 |
Why?
|
| Receptors, Muscarinic | 1 | 2013 | 157 | 0.100 |
Why?
|
| Organ Size | 1 | 2017 | 2254 | 0.100 |
Why?
|
| Prostaglandin D2 | 1 | 2012 | 108 | 0.100 |
Why?
|
| Child, Preschool | 10 | 2024 | 42230 | 0.100 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2012 | 96 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2016 | 606 | 0.100 |
Why?
|
| Chemotaxis | 1 | 2015 | 598 | 0.100 |
Why?
|
| Kinetics | 2 | 2019 | 6374 | 0.100 |
Why?
|
| Iris | 2 | 2004 | 232 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2017 | 823 | 0.100 |
Why?
|
| Myopia | 1 | 1994 | 253 | 0.100 |
Why?
|
| Prednisone | 1 | 2016 | 1563 | 0.100 |
Why?
|
| Disaccharides | 1 | 2012 | 170 | 0.100 |
Why?
|
| Injections, Intraocular | 1 | 2011 | 33 | 0.100 |
Why?
|
| Receptors, Androgen | 4 | 2002 | 1079 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 4544 | 0.100 |
Why?
|
| Japan | 3 | 2021 | 1378 | 0.100 |
Why?
|
| Pain | 1 | 2007 | 5073 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2012 | 168 | 0.100 |
Why?
|
| Trigeminal Ganglion | 1 | 2012 | 190 | 0.100 |
Why?
|
| Efferent Pathways | 1 | 2012 | 165 | 0.100 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2012 | 140 | 0.090 |
Why?
|
| Epoprostenol | 1 | 2012 | 247 | 0.090 |
Why?
|
| Gamma Rays | 1 | 2012 | 318 | 0.090 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 9539 | 0.090 |
Why?
|
| Mannose-Binding Lectins | 1 | 2011 | 96 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 1996 | 521 | 0.090 |
Why?
|
| Angiogenic Proteins | 1 | 2011 | 101 | 0.090 |
Why?
|
| Afferent Pathways | 1 | 2012 | 298 | 0.090 |
Why?
|
| Blood | 1 | 2013 | 596 | 0.090 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2011 | 223 | 0.090 |
Why?
|
| Disease | 1 | 2016 | 672 | 0.090 |
Why?
|
| Injections | 2 | 2007 | 830 | 0.090 |
Why?
|
| Gene Silencing | 2 | 2007 | 1509 | 0.090 |
Why?
|
| Orbit | 1 | 1994 | 457 | 0.090 |
Why?
|
| Umbilical Veins | 1 | 2011 | 426 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 15266 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2020 | 1936 | 0.090 |
Why?
|
| Photography | 1 | 2013 | 532 | 0.090 |
Why?
|
| Surface Plasmon Resonance | 1 | 2011 | 269 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 522 | 0.090 |
Why?
|
| Regeneration | 1 | 2019 | 1511 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 1994 | 683 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2017 | 6228 | 0.080 |
Why?
|
| Clodronic Acid | 1 | 2009 | 59 | 0.080 |
Why?
|
| Postmenopause | 4 | 2002 | 2513 | 0.080 |
Why?
|
| Nerve Regeneration | 1 | 2015 | 795 | 0.080 |
Why?
|
| Etoposide | 1 | 2011 | 634 | 0.080 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 1087 | 0.080 |
Why?
|
| Patient Satisfaction | 3 | 2016 | 3461 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2012 | 597 | 0.080 |
Why?
|
| Dogs | 2 | 2004 | 3839 | 0.080 |
Why?
|
| History, 21st Century | 2 | 2007 | 1567 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 3415 | 0.080 |
Why?
|
| Military Personnel | 1 | 2018 | 1246 | 0.080 |
Why?
|
| ROC Curve | 1 | 2017 | 3579 | 0.080 |
Why?
|
| Tubulin | 1 | 2013 | 693 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 9280 | 0.080 |
Why?
|
| Logistic Models | 3 | 2019 | 13255 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1995 | 807 | 0.080 |
Why?
|
| Rural Health | 1 | 1990 | 296 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 629 | 0.080 |
Why?
|
| Sodium Hydroxide | 3 | 2017 | 37 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2019 | 1189 | 0.080 |
Why?
|
| Cell Separation | 2 | 2014 | 1720 | 0.080 |
Why?
|
| Single-Blind Method | 4 | 2015 | 1572 | 0.080 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2009 | 146 | 0.080 |
Why?
|
| Vision, Low | 1 | 1990 | 163 | 0.080 |
Why?
|
| Sensation | 1 | 2010 | 337 | 0.080 |
Why?
|
| Nerve Fibers | 2 | 2010 | 708 | 0.080 |
Why?
|
| Antigen Presentation | 3 | 2003 | 1251 | 0.080 |
Why?
|
| Rats | 7 | 2021 | 23742 | 0.080 |
Why?
|
| Stereotaxic Techniques | 1 | 2011 | 555 | 0.080 |
Why?
|
| Dexamethasone | 2 | 2024 | 1948 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2018 | 6343 | 0.080 |
Why?
|
| Glycoconjugates | 1 | 2008 | 88 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2020 | 23995 | 0.080 |
Why?
|
| Parasympathetic Nervous System | 1 | 2009 | 142 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 258 | 0.080 |
Why?
|
| Stromal Cells | 2 | 2019 | 1330 | 0.080 |
Why?
|
| Retreatment | 1 | 2009 | 598 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 1590 | 0.070 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2007 | 57 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2455 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 3416 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2002 | 702 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2012 | 1510 | 0.070 |
Why?
|
| Progesterone | 2 | 2002 | 742 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 1062 | 0.070 |
Why?
|
| Acanthamoeba | 1 | 2007 | 12 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 710 | 0.070 |
Why?
|
| Child | 11 | 2024 | 80153 | 0.070 |
Why?
|
| Antidepressive Agents | 2 | 2017 | 2897 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 2469 | 0.070 |
Why?
|
| Nitriles | 1 | 2012 | 971 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 2011 | 1606 | 0.070 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2007 | 71 | 0.070 |
Why?
|
| Suture Techniques | 3 | 1997 | 769 | 0.070 |
Why?
|
| Health Status | 1 | 2020 | 4077 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 899 | 0.070 |
Why?
|
| Estrogens | 3 | 2002 | 1522 | 0.070 |
Why?
|
| Macrophage-1 Antigen | 1 | 2007 | 285 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2017 | 344 | 0.070 |
Why?
|
| Random Allocation | 2 | 2001 | 2395 | 0.070 |
Why?
|
| Prognosis | 6 | 2020 | 29625 | 0.070 |
Why?
|
| Multivariate Analysis | 5 | 2003 | 12059 | 0.070 |
Why?
|
| Endothelium | 1 | 2009 | 765 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 2024 | 0.070 |
Why?
|
| Antiprotozoal Agents | 2 | 2015 | 94 | 0.070 |
Why?
|
| Microcirculation | 1 | 2011 | 1273 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 691 | 0.070 |
Why?
|
| Chemokines, CC | 1 | 2007 | 283 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2206 | 0.070 |
Why?
|
| Arteries | 1 | 2011 | 1123 | 0.060 |
Why?
|
| Sympathetic Nervous System | 1 | 2009 | 518 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 1206 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 13446 | 0.060 |
Why?
|
| Liposomes | 1 | 2009 | 784 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 539 | 0.060 |
Why?
|
| Suppuration | 1 | 2005 | 60 | 0.060 |
Why?
|
| Chemokine CCL3 | 1 | 2005 | 84 | 0.060 |
Why?
|
| Skin | 2 | 2013 | 4484 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2811 | 0.060 |
Why?
|
| Leukemic Infiltration | 1 | 2005 | 47 | 0.060 |
Why?
|
| Skin Transplantation | 2 | 2009 | 1083 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 1351 | 0.060 |
Why?
|
| Air | 1 | 2005 | 187 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 12974 | 0.060 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2007 | 323 | 0.060 |
Why?
|
| Defective Viruses | 1 | 2004 | 89 | 0.060 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2002 | 74 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2011 | 3087 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2009 | 1093 | 0.060 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2005 | 224 | 0.060 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2005 | 225 | 0.060 |
Why?
|
| Prosthesis Implantation | 2 | 2016 | 592 | 0.060 |
Why?
|
| Histocompatibility Antigens | 2 | 2009 | 464 | 0.060 |
Why?
|
| Risk | 1 | 2016 | 9610 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 731 | 0.060 |
Why?
|
| Sclera | 2 | 1995 | 190 | 0.060 |
Why?
|
| MMPI | 1 | 1983 | 81 | 0.060 |
Why?
|
| Receptors, Notch | 1 | 2008 | 743 | 0.060 |
Why?
|
| Comorbidity | 1 | 2018 | 10508 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2009 | 944 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2017 | 9000 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2012 | 1541 | 0.060 |
Why?
|
| Sex Factors | 1 | 2017 | 10552 | 0.060 |
Why?
|
| Pregnancy | 2 | 2023 | 29874 | 0.050 |
Why?
|
| Thrombospondins | 1 | 2004 | 193 | 0.050 |
Why?
|
| Androgen Antagonists | 4 | 2002 | 1410 | 0.050 |
Why?
|
| Neuropilin-2 | 1 | 2003 | 55 | 0.050 |
Why?
|
| Schizophrenia, Paranoid | 1 | 1983 | 103 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 5146 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 4063 | 0.050 |
Why?
|
| Caspases | 1 | 2006 | 879 | 0.050 |
Why?
|
| Infant | 7 | 2024 | 36192 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 2822 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2018 | 7967 | 0.050 |
Why?
|
| Splenectomy | 2 | 2002 | 391 | 0.050 |
Why?
|
| Macaca | 1 | 2004 | 410 | 0.050 |
Why?
|
| Societies, Scientific | 1 | 2004 | 222 | 0.050 |
Why?
|
| Wettability | 1 | 2002 | 27 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3084 | 0.050 |
Why?
|
| Phospholipids | 1 | 2006 | 786 | 0.050 |
Why?
|
| Florida | 1 | 2004 | 431 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 2571 | 0.050 |
Why?
|
| Decision Making | 1 | 2016 | 3929 | 0.050 |
Why?
|
| Chemistry, Physical | 1 | 2002 | 154 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3204 | 0.050 |
Why?
|
| Psychometrics | 3 | 2016 | 3065 | 0.050 |
Why?
|
| Retinitis | 1 | 2002 | 36 | 0.050 |
Why?
|
| Rupture | 2 | 2002 | 443 | 0.050 |
Why?
|
| Chemical Phenomena | 1 | 2002 | 507 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 795 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 1 | 2005 | 544 | 0.050 |
Why?
|
| Wisconsin | 1 | 2002 | 122 | 0.050 |
Why?
|
| Cadaver | 2 | 2017 | 1358 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 3429 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 452 | 0.050 |
Why?
|
| Health Occupations | 1 | 2003 | 222 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2009 | 4580 | 0.050 |
Why?
|
| Health Status Indicators | 2 | 2006 | 970 | 0.050 |
Why?
|
| Ciliary Body | 1 | 2002 | 167 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2004 | 376 | 0.050 |
Why?
|
| Neoplasms | 3 | 2020 | 22170 | 0.050 |
Why?
|
| Maryland | 1 | 2002 | 277 | 0.050 |
Why?
|
| Nuclease Protection Assays | 1 | 2000 | 14 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 13639 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2017 | 2496 | 0.050 |
Why?
|
| Neuroprotective Agents | 2 | 2018 | 957 | 0.050 |
Why?
|
| Women's Health | 3 | 2007 | 2065 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8654 | 0.040 |
Why?
|
| Boston | 1 | 2013 | 9326 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2002 | 363 | 0.040 |
Why?
|
| Orchiectomy | 2 | 1999 | 463 | 0.040 |
Why?
|
| Mice, Inbred A | 1 | 1999 | 246 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2018 | 2155 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 326 | 0.040 |
Why?
|
| Neck | 2 | 2002 | 734 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 1134 | 0.040 |
Why?
|
| Awards and Prizes | 1 | 2004 | 360 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 2 | 2017 | 811 | 0.040 |
Why?
|
| Lasers | 1 | 2004 | 952 | 0.040 |
Why?
|
| Gene Library | 1 | 2002 | 1059 | 0.040 |
Why?
|
| Feminization | 1 | 1999 | 19 | 0.040 |
Why?
|
| Hypophysectomy | 1 | 1999 | 114 | 0.040 |
Why?
|
| Software | 1 | 2013 | 4434 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2006 | 1301 | 0.040 |
Why?
|
| Vitamin E | 1 | 2003 | 872 | 0.040 |
Why?
|
| Solubility | 1 | 2000 | 1091 | 0.040 |
Why?
|
| Lead | 1 | 2004 | 879 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2002 | 1991 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 1999 | 293 | 0.040 |
Why?
|
| Temperature | 1 | 2005 | 2226 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2020 | 472 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2024 | 41487 | 0.040 |
Why?
|
| Nandrolone | 1 | 1998 | 17 | 0.040 |
Why?
|
| Acute Disease | 3 | 2011 | 7237 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 210 | 0.040 |
Why?
|
| Australia | 1 | 2002 | 1250 | 0.040 |
Why?
|
| Myocardium | 1 | 2011 | 4726 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 1999 | 285 | 0.040 |
Why?
|
| Commerce | 1 | 2023 | 606 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 1999 | 422 | 0.040 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2018 | 91 | 0.040 |
Why?
|
| Uvea | 1 | 2017 | 30 | 0.040 |
Why?
|
| Algorithms | 2 | 2019 | 14031 | 0.040 |
Why?
|
| Alkalies | 1 | 2017 | 44 | 0.040 |
Why?
|
| Tetrahydrocortisol | 1 | 1996 | 1 | 0.040 |
Why?
|
| Biopsy | 2 | 2023 | 6766 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 962 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 1999 | 605 | 0.040 |
Why?
|
| Bandages | 1 | 2019 | 269 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2002 | 1336 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1999 | 614 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2012 | 8481 | 0.030 |
Why?
|
| Astigmatism | 1 | 1997 | 68 | 0.030 |
Why?
|
| Diclofenac | 1 | 1996 | 68 | 0.030 |
Why?
|
| Neutrophils | 1 | 2009 | 3767 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 6075 | 0.030 |
Why?
|
| Safety | 1 | 2001 | 1150 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2005 | 1390 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1999 | 647 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2012 | 7856 | 0.030 |
Why?
|
| Odds Ratio | 3 | 2020 | 9646 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2019 | 687 | 0.030 |
Why?
|
| Prednisolone | 1 | 1996 | 326 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 1749 | 0.030 |
Why?
|
| Dacryocystorhinostomy | 1 | 2016 | 78 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2115 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2021 | 714 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 8002 | 0.030 |
Why?
|
| Spleen | 1 | 2001 | 2295 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
| Forecasting | 1 | 2004 | 2928 | 0.030 |
Why?
|
| Stage-Specific Embryonic Antigens | 1 | 2014 | 7 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2001 | 1165 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 8181 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2006 | 353 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2002 | 2639 | 0.030 |
Why?
|
| Transducers, Pressure | 1 | 1994 | 51 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 1983 | 1797 | 0.030 |
Why?
|
| Ectoderm | 1 | 2014 | 137 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 7390 | 0.030 |
Why?
|
| Keratinocytes | 1 | 1998 | 790 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2020 | 2202 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 999 | 0.030 |
Why?
|
| Amblyopia | 1 | 1995 | 150 | 0.030 |
Why?
|
| Keratin-3 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2019 | 2048 | 0.030 |
Why?
|
| Light | 1 | 2019 | 1353 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 1277 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 1741 | 0.030 |
Why?
|
| Cyclooxygenase 1 | 1 | 2012 | 97 | 0.030 |
Why?
|
| Mast Cells | 1 | 1999 | 1392 | 0.030 |
Why?
|
| Lung | 1 | 2011 | 10000 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 105 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 352 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 1458 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2019 | 1014 | 0.020 |
Why?
|
| Galectins | 1 | 2015 | 295 | 0.020 |
Why?
|
| Sheep | 1 | 1994 | 1440 | 0.020 |
Why?
|
| Allergens | 1 | 1999 | 1432 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 1334 | 0.020 |
Why?
|
| Recurrence | 2 | 2011 | 8465 | 0.020 |
Why?
|
| Fatty Acids | 3 | 2006 | 1808 | 0.020 |
Why?
|
| Aspirin | 1 | 2003 | 3133 | 0.020 |
Why?
|
| Lipocalins | 1 | 2012 | 161 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 290 | 0.020 |
Why?
|
| Vitreous Body | 1 | 1993 | 399 | 0.020 |
Why?
|
| Cell Shape | 1 | 2012 | 371 | 0.020 |
Why?
|
| Testosterone | 1 | 2002 | 2472 | 0.020 |
Why?
|
| Amnion | 1 | 2012 | 197 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 2219 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2021 | 2911 | 0.020 |
Why?
|
| Dermis | 1 | 2012 | 202 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 1983 | 2471 | 0.020 |
Why?
|
| Kentucky | 1 | 1990 | 84 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2012 | 1085 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 2 | 2011 | 753 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2024 | 26198 | 0.020 |
Why?
|
| Cell Size | 1 | 2012 | 624 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 1436 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1886 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 597 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2021 | 2521 | 0.020 |
Why?
|
| Mutation | 2 | 2024 | 30052 | 0.020 |
Why?
|
| Age of Onset | 1 | 1997 | 3305 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2005 | 1596 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1998 | 2767 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2004 | 4486 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2015 | 1173 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2014 | 757 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2016 | 1468 | 0.020 |
Why?
|
| Virus Activation | 1 | 2011 | 322 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 621 | 0.020 |
Why?
|
| Imidazoles | 1 | 2015 | 1180 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1990 | 882 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2015 | 1502 | 0.020 |
Why?
|
| Research Design | 1 | 2004 | 6180 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2002 | 3242 | 0.020 |
Why?
|
| Nervous System | 1 | 2011 | 545 | 0.020 |
Why?
|
| Diet | 2 | 2003 | 8075 | 0.020 |
Why?
|
| Corneal Topography | 1 | 2007 | 68 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 3778 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 1999 | 3826 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2011 | 988 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 799 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 1992 | 1204 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2018 | 3763 | 0.020 |
Why?
|
| Phagocytes | 1 | 2008 | 295 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1188 | 0.020 |
Why?
|
| Destrin | 1 | 2005 | 10 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1732 | 0.020 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2005 | 42 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 521 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 2555 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2008 | 910 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 266 | 0.010 |
Why?
|
| Body Burden | 1 | 2004 | 158 | 0.010 |
Why?
|
| Bacteria | 1 | 1995 | 2199 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 1994 | 2093 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 27112 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 11742 | 0.010 |
Why?
|
| Proteins | 1 | 2019 | 6032 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 2004 | 326 | 0.010 |
Why?
|
| Endothelium, Lymphatic | 1 | 2003 | 63 | 0.010 |
Why?
|
| Macular Degeneration | 1 | 1990 | 1007 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 1667 | 0.010 |
Why?
|
| Growth Substances | 1 | 2005 | 768 | 0.010 |
Why?
|
| Iron, Dietary | 1 | 2003 | 148 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 2004 | 322 | 0.010 |
Why?
|
| Mucin 5AC | 1 | 2002 | 96 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 1990 | 1274 | 0.010 |
Why?
|
| Laser Coagulation | 1 | 2003 | 330 | 0.010 |
Why?
|
| Lipids | 2 | 2002 | 3341 | 0.010 |
Why?
|
| Vitamin B 6 | 1 | 2002 | 234 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 1699 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 3617 | 0.010 |
Why?
|
| Depression | 1 | 2020 | 8124 | 0.010 |
Why?
|
| Viscosity | 1 | 2000 | 336 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 2003 | 529 | 0.010 |
Why?
|
| Germany | 1 | 2002 | 875 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 1060 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2003 | 15500 | 0.010 |
Why?
|
| Chickens | 1 | 2002 | 859 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2927 | 0.010 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 9420 | 0.010 |
Why?
|
| Vitamin A | 1 | 2003 | 613 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2003 | 1848 | 0.010 |
Why?
|
| Zinc | 1 | 2003 | 690 | 0.010 |
Why?
|
| Nerve Net | 1 | 2010 | 2290 | 0.010 |
Why?
|
| Insurance, Health | 1 | 1990 | 2498 | 0.010 |
Why?
|
| Interleukins | 1 | 2003 | 782 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 2819 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 1416 | 0.010 |
Why?
|
| Models, Biological | 1 | 2014 | 9469 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 2421 | 0.010 |
Why?
|
| Complement C3 | 1 | 1999 | 435 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1990 | 7827 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 751 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 10209 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 1271 | 0.010 |
Why?
|
| Allergy and Immunology | 1 | 1997 | 176 | 0.010 |
Why?
|
| Refraction, Ocular | 1 | 1997 | 184 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 1995 | 128 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2002 | 2192 | 0.010 |
Why?
|
| Cefazolin | 1 | 1995 | 94 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 1937 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2001 | 1349 | 0.010 |
Why?
|
| Reflex, Pupillary | 1 | 1994 | 62 | 0.010 |
Why?
|
| Gentamicins | 1 | 1995 | 243 | 0.010 |
Why?
|
| Cephalosporins | 1 | 1995 | 198 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 1995 | 275 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2004 | 2568 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2002 | 1995 | 0.010 |
Why?
|
| Culture Media | 1 | 1995 | 897 | 0.010 |
Why?
|
| Autoantigens | 1 | 1997 | 891 | 0.010 |
Why?
|
| Health Personnel | 1 | 2007 | 3335 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 1990 | 5440 | 0.010 |
Why?
|
| Proteomics | 1 | 2006 | 3849 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12441 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 3188 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1997 | 1784 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 17635 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2002 | 5112 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1995 | 1937 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2002 | 3415 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1989 | 945 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1997 | 3156 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1999 | 12463 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 7594 | 0.000 |
Why?
|
| Age Factors | 1 | 1999 | 18395 | 0.000 |
Why?
|